A5074349466- Occupational and environmental lung diseases
- Myasthenia Gravis and Thymoma
- Pleural and Pulmonary Diseases
- Cancer Research and Treatments
- Medical Imaging and Pathology Studies
- Neuroblastoma Research and Treatments
- Cancer Immunotherapy and Biomarkers
- Renal cell carcinoma treatment
- Lung Cancer Treatments and Mutations
- Pituitary Gland Disorders and Treatments
- Interstitial Lung Diseases and Idiopathic Pulmonary Fibrosis
- Bladder and Urothelial Cancer Treatments
- Cancer Treatment and Pharmacology
- Prostate Cancer Treatment and Research
- Glioma Diagnosis and Treatment
- Urinary and Genital Oncology Studies
- Cancer, Lipids, and Metabolism
- Radiomics and Machine Learning in Medical Imaging
- Renal and related cancers
- Cancer Diagnosis and Treatment
- Neuroendocrine Tumor Research Advances
- Ferroptosis and cancer prognosis
- Peptidase Inhibition and Analysis
- MRI in cancer diagnosis
- Economic and Financial Impacts of Cancer
IRCCS Humanitas Research Hospital
2015-2025
Humanitas University
2015-2024
Istituti di Ricovero e Cura a Carattere Scientifico
2012-2023
Medica (Italy)
2013-2020
Fondazione Humanitas per la Ricerca
2011-2019
University of Milan
2017
Amsterdam UMC Location Vrije Universiteit Amsterdam
2011
Purpose No effective salvage treatments are available for patients with advanced/recurrent thymoma (T) or thymic carcinoma (TC) who have progressed after platinum-based chemotherapy. This study evaluated the activity of everolimus in T TC previously treated cisplatin-containing Patients and Methods was a single-arm, single-stage, open-label, multicenter, phase II trial. received oral 10 mg/d until disease progression, unacceptable toxicity, patient refusal. A Fleming trial designed. The null...
Background: Despite the survival advantage, not all metastatic renal cell carcinoma (mRCC) patients achieve a long-term benefit from immunotherapy. Moreover, identification of prognostic biomarkers is still an unmet clinical need. Methods: This multicenter retrospective study investigated role peripheral-blood inflammatory indices and factors to develop novel score in mRCC receiving at least second-line nivolumab. The complete blood count before first cycle therapy was assessed by...
Immune checkpoint inhibitors (ICIs) revolutionized cancer therapy, yet require management of immune-related adverse events (irAEs). Fulminant myocarditis is a rare irAE, but lower-severity cardiac are being reported more frequently, leading to an unmet need for irAE prevention, early diagnosis, and treatment, especially long-life-expectancy patients. We recruited 57 patients, stratified according therapy regime (monotherapy (30%) or combination (33%) cohort) history disease presence at least...
The pemetrexed/platinum agent combination represents the standard of care in first-line treatment for malignant pleural mesothelioma (MPM). However, there are no established indicators responsiveness that can be used to optimize treatment. This retrospective study aimed assess role excision repair cross-complementing group-1 (ERCC1) and thymidylate synthase (TS) tumors, correlate expression levels polymorphisms these key determinants drug activity with outcome MPM patients treated...
Background We aimed to investigate prevalence and prognostic role of SOX2, PIK3CA, FGFR1 BRF2 gene gain in patients with surgically resected non-small cell lung cancer (NSCLC). Methods copy number was assessed by fluorescence situ hybridization (FISH) arrayed tissue cores from 447 NSCLCs. Results Increased (FISH+) for observed 23.6%, 29.2%, 16.6% 14.9% cases, respectively. FISH+ status each significantly associated smoking history, squamous carcinoma (SCC) histology, increased the other...
Background Preclinical data suggest that concurrent treatment of anti-CD38 and antiprogrammed death 1 (PD-1)/programmed ligand (PD-L1) antibodies substantially reduce primary tumor growth by reversing T-cell exhaustion thus enhancing anti-PD-1/PD-L1 efficacy. Methods This phase I/II study enrolled patients with metastatic castration-resistant prostate cancer (mCRPC) or advanced non-small cell lung (NSCLC). The objectives I were to investigate the safety tolerability isatuximab (anti-CD38...
Combinations of VEGFR-TKIs plus ICI against PD1/PD-L1 are the standard first-line therapy for patients with mRCC, irrespective prognostic class. This study aims to investigate feasibility and safety withdrawing VEGFR-TKI but continuing anti- in who achieve response their combination.
Background: thymic basaloid carcinoma (BTC) is an extremely rare tumor, and very little data are available on BTC’s biology, clinical behavior, drug sensitivity, patient outcomes. Methods: We performed a retrospective observational study patients diagnosed with BTC in 11 referral centers of TYME. All diagnoses were reviewed by the referring pathologist. Results: Twenty-eight identified. A total 22/28 included. Eighteen had TNM stage I–III disease, all underwent surgery; three received...
584 Background: KIM-1 was evaluated as plasma circulating biomarker of microscopical residual disease, disease recurrence after nephrectomy, and potential benefit from adjuvant immunotherapy (IO). No data are available about its role in the metastatic setting. Tide-A is a phase 2 trial showing feasibility de-intensified strategy VEGFR-TKI interruption IO-maintenance mRCC pts treated with ave+axi. We investigated whether prognostic prospective cohort Tide-A. Methods: Treatment-naïve prior no...
551 Background: Combinations of therapies with VEGFR-TKI (TKI) and anti-PD1/PDL1 immunotherapy (IO) are considered the standard care for first line treatment patients (pts) mRCC. The Tide-A trial previously reported feasibility TKI interruption maintenance in pts achieving tumor response after TKI+IO combination, its primary endpoint. Here we updated results a longer follow-up. Methods: Pts surgery tumor, without symptomatic/bulky disease or liver mets, were treated Ave 800 mg flat dose IV...
Thymic epithelial tumors (TETs) are rare mediastinal cancers originating from the thymus, classified in two main histotypes: thymoma and thymic carcinoma (TC). TETs affect a primary lymphoid organ playing critical role keeping T-cell homeostasis ensuring an adequate immunological tolerance against “self”. In particular, thymomas not TC frequently associated with autoimmune diseases (ADs), Myasthenia Gravis being most common AD present 30% of patients thymoma. This comorbidity, addition to...
7527 Background: Alterations of the serine-threonine kinase mammalian target rapamycin (mTOR) signalling pathway are common in cancer, and thus mTOR is being actively pursued as a therapeutic target. In particular, emerging potential target, following tumor responses observed phase I trials, with recent data from several groups. The aim this study to determine activity Everolimus monotherapy patients (pts) advanced or recurrent thymoma (T) thymic carcinoma (TC) previously treated...
We examined a series of malignant pleural mesothelioma (MPM) patients who underwent radical surgery to explore relationships among comorbidity, postoperative morbidity and survival. A retrospective analysis was carried out all MPM operated on in single centre from 2000 2015. The Charlson Comorbidity Index (CCI) used classify according their underlying condition. Postoperative complications were scored WHO-derived criteria. Survival comparisons performed by Cox analysis. Ninety-one...